Previous close | 6.30 |
Open | 5.84 |
Bid | 5.70 |
Ask | 6.15 |
Strike | 10.00 |
Expiry date | 2024-10-18 |
Day's range | 5.30 - 5.85 |
Contract range | N/A |
Volume | |
Open interest | 403 |
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Whitefort Capital wants biopharmaceutical firm Arbutus to stop issuing stock. Shah Capital ended a proxy campaign against biotech Novavax.